Signatera is a personalized blood test that detects cancer recurrence by identifying a patient's unique tumor DNA fingerprint. Unlike general cancer markers, Signatera's high sensitivity allows for early detection of minimal residual disease (MRD) and helps assess treatment response. This early detection capability enables quicker intervention, potentially improving patient outcomes and reducing uncertainty. The test involves a one-time tumor DNA analysis followed by periodic blood draws to monitor ctDNA levels, guiding personalized cancer care. Ultimately, Signatera offers a more precise and proactive approach to cancer monitoring compared to traditional methods.